Covaxin phase 3 data shows 77.8% efficacy against symptomatic Covid-19, says Lancet

After the World Health Organization (WHO) approved Bharat Biotech’s Covaxin for emergency use, medical journal Lancet has now said that the made-in-India vaccine is 77.8 per cent effective against symptomatic COVID, as per Phase 3 data. Get to know from. The efficacy data demonstrated 70.8 percent protection against all variants of the SARS-CoV-2 virus.

The efficacy rate was confirmed through an evaluation of 130 confirmed cases, with 24 seen in the vaccine group against 106 in the placebo group.

As per the Phase 3 data, Covaxin was found to be 65.2 percent effective against delta variant, 93.4 percent effective against severe symptomatic COVID and 63.6 percent effective against asymptomatic COVID.

Dr Krishna Ella, CMD, Bharat Biotech, said, “An authoritative voice in global medicine, The Lancet has the potential for peer-review of Covaxin Phase III clinical trial data, data transparency and meeting the world’s stringent peer-review standards. -Leading medical journals. This achievement reflects the trust placed by my team members at Bharat Biotech, our public partners, the Indian Council of Medical Research, the National Institute of Virology and our trial participants who have done so. did.

The Phase 3 trial efficacy and safety study involved 25,800 volunteers at 25 sites in India and is the country’s largest clinical trial so far conducted for a COVID-19 vaccine.

Dr. Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) said, “I am pleased to see that Phase III efficacy data has also been published in The Lancet, one of the most prestigious journals across the world. This in itself speaks highly of Covaxin’s strong position among other global front-runner COVID-19 vaccines.”

He said, “Covaxin’s bedside visit in less than 10 months showcased the immense strength of “Atmanirbhar Bharat” in building a niche in the global community along with Indian academia and industry and fighting against the odds.”

On 3 November, the World Health Organization approved emergency use for Bharat Biotech’s COVID-19 vaccine Covaxin, in a move the pharma major said was a “critical step” towards ensuring wider global access to the indigenously developed jab. “Step.

An independent advisory committee of the world body, announced by the WHO after the Technical Advisory Group (TAG), recommended emergency use list (EUL) status for Covaxin, and “additional clarification” from Bharat Biotech by TAG in October A few days after being asked. 26 To conduct a final “risk-benefit assessment” of the vaccine for global use.